FRASE-bot was applied to identify potential agents against Triple Negative Breast Cancer (TNBC) by targeting Calcium- and Integrin-Binding Protein 1 (CIB1)30–32. This evidence concerns the gene CIB1 and triple-negative breast carcinoma.